急性骨髓性白血病治療市場（依治療類型、作用機制、治療線、最終使用者、給藥途徑及病患年齡分類）－2025-2032年全球預測

預計到 2032 年，急性骨髓性白血病治療市場規模將成長 26.1 億美元，複合年成長率為 12.46%。

關鍵市場統計數據
基準年 2024	10.2億美元
預計年份：2025年	11.4億美元
預測年份 2032	26.1億美元
複合年成長率 (%)	12.46%

本文簡明扼要地概述了急性骨髓性白血病治療的發展歷程，重點介紹了其臨床複雜性、精準治療方法和商業性重要性。

急性骨髓性白血病(AML) 是臨床上最複雜的骨髓惡性腫瘤之一，其特徵是遺傳因素異質性、患者群體多樣化以及治療模式不斷演變。過去十年，治療方法已從廣譜細胞毒性方案轉向精準標靶治療和免疫腫瘤治療方法。這一轉變得益於對分子機制的深入理解、診斷分層技術的改進以及先進生物製藥和細胞療法的成熟。因此，研究、臨床和商業領域的相關人員面臨著一個快速變化的環境，需要採取相應的適應性策略。

臨床醫生目前需要在既定的治療方案推廣和維持框架與不斷擴充的標靶抑制劑、表觀遺傳調變器和細胞療法等治療手段之間尋求平衡。同時，支付方和醫療服務體係也正在調整報銷方式，以兼顧高成本的一次性治療和長期療效。這些動態變化既為製造商、合約研究與受託製造廠商以及供應鏈合作夥伴帶來了機遇，也帶來了營運上的複雜性。因此，對於在急性髓性白血病（AML）治療領域做出投資、合作和產品上市決策的領導者而言，清晰且切實地整合臨床趨勢、監管變化和商業性需求至關重要。

本書權威地探討了科學、監管和商業性力量的融合如何重塑急性骨髓性白血病藥物的研發和上市。

急性骨髓性白血病）的治療格局正在經歷一場變革，這主要得益於科學進步、監管環境的演變以及商業性創新三者的共同推動。精準醫療已從概念階段邁向臨床實踐階段，基因組分析和微量殘存疾病檢測等技術使得患者篩選更加精準，治療策略也更具適應性。同時，生物製劑平台（包括抗體藥物複合體和融合蛋白）的日益成熟，拓展了治療適應症，並實現了靶向細胞毒性藥物遞送，進一步促進了這一轉變。此外，細胞療法的研發和規模化生產帶來了持久療效的可能，同時也對生產和物流提出了獨特的要求。

同時，監管框架也在不斷發展，以適應新型治療方法和替代終點。支付方正積極回應，推出基於價值的合約試點計畫和基於結果的報銷模式，將初始成本與療效的持久性掛鉤。產業聯盟蓬勃發展，匯聚藥物研發、轉化科學和商業性准入等方面的專業知識，改變了傳統的競爭動態。因此，成功越來越依賴整合臨床開發、供應鏈準備和支付方參與的整合策略，而非以產品為中心的獨立計畫。

對2025年貿易政策累積影響對AML藥物供應鏈、生產投資選擇與取得途徑的清晰分析

2025年高關稅制度的實施和貿易政策的轉變將對急性髓系白血病（AML）治療價值鏈產生顯著的連鎖反應，其累積影響主要體現在供應鏈韌性、生產策略以及患者成本動態等。生技藥品和細胞療法生產中使用的依賴進口的組件，包括專用試劑、一次性系統和關鍵設備，其採購模式已發生轉變，促使製造商和合約合作夥伴重新評估採購區域和庫存緩衝。為此，一些相關人員加快了近岸外包的步伐，並使其供應商網路多元化，以降低關稅相關干擾帶來的風險。

除了採購之外，關稅也影響了新生產能力的資本投資決策，尤其是那些需要專用無塵室設施和低溫運輸基礎設施的複雜配方產品。計劃新建工廠的公司需要在不斷上漲的設備和零件進口關稅與區域供應安全的長期戰略需求之間權衡利弊。此外，進口原料到岸成本的上升也給價格談判和分銷協議帶來了壓力，進而影響了醫院和專科診所的癌症藥物預算。這些壓力凸顯了製造商和支付方之間進行透明成本分析和建立協作合約機制的必要性。

最後，關稅政策日益強調監管和海關協調，以減少行政延誤，從而降低貿易措施帶來的經濟影響。相關人員積極與政策制定者和產業協會合作，以明確生物製藥和先進治療成分的關稅分類，並在國家衛生優先事項需要加快取得途徑時，爭取豁免。因此，那些積極調整籌資策略、加強區域製造地並與政策制定者進行建設性溝通的公司，已在不斷變化的貿易環境中佔據有利地位，能夠維持供應的連續性並保障患者的用藥需求。

全面的細分分析揭示了治療方式、機制、治療環境、給藥途徑和患者人口統計特徵如何決定臨床和商業策略。

細分洞察揭示了不同療法類型、作用機制、治療線、最終用戶、給藥途徑和患者族群所帶來的差異化商業機會和營運需求。治療方法方案多種多樣，包括生物製藥（如抗體藥物複合體、融合蛋白和單株抗體）、細胞療法（如CAR-T療法和幹細胞移植）、基因療法、BCL-2抑制劑、DNA甲基轉移酶抑制劑和蛋白酪氨酸激酶抑制劑，以及小分子藥物（可細分為標靶FLT3和KIT的藥物）。這種治療模式的細分對臨床試驗設計、生產複雜性和核准後證據的產生有顯著影響。

基於機制的細分方法揭示了BCL-2抑制、DNA甲基轉移酶抑制劑介導的表觀遺傳修飾、組蛋白去乙醯化酶修飾、免疫調節劑以及蛋白酪氨酸激酶抑制劑如何對聯合治療策略和抗藥性管理產生不同的影響。就治療線而言，第一線治療方案優先考慮新診斷族群的持久性和耐受性，二線治療方案強調挽救性療效和安全性，而三線及後續治療方案則著重於克服獲得性抗藥性和控制累積毒性。終端用戶細分方法強調，醫院藥房必須協調住院患者的給藥和複雜生技藥品的低溫運輸儲存，零售藥房負責門診口服藥物的配藥，而專科診所則在高度控制的條件下提供先進的細胞療法。

按給藥途徑細分，可區分靜脈輸液療法（需要輸液基礎設施和監測）和口服藥物（可在家中服用，但需要依從性支持）；皮下注射可減輕輸液負擔，但需要患者教育和給藥培訓。依患者年齡細分，可知成人患者佔治療決策的大多數，老年患者通常需要調整劑量和合併症管理，而兒童患者則需要考慮安全性和發育因素。整合這些細分訊息，有助於相關人員確定臨床開發路徑的優先順序，協調生產和分銷投資，並根據不同的給藥方式、機制、護理環境和患者群體，制定差異化的市場開發方法。

詳細的區域展望，重點介紹主要全球市場在市場促進因素、監管預期和營運重點方面的差異

區域洞察凸顯了美洲、中東和非洲以及亞太地區在應用促進因素、監管預期和營運重點方面的差異，這些差異對臨床開發和商業化都有獨特的影響。在美洲，分散的支付方結構和先進的報銷機制與強大的臨床試驗網路和成熟的腫瘤中心並存，這使得證據生成和價值論證對於高階產品的獲取和應用至關重要。相反，在中東和非洲，集中化的法律規範和不同的報銷門檻凸顯了衛生技術評估和區域定價策略的重要性。

亞太地區擁有龐大的患者群體、不斷提升的診斷能力和日益擴大的生產能力，因此具備加速推廣應用的潛力。然而，該地區管理體制的多樣性和成本敏感性也使其需要製定區域性的臨床開發計劃和靈活的商業模式。在任何地區，低溫運輸的穩定性、本地生產夥伴關係以及快速的監管反應等物流因素都會對產品上市順序和市場准入時間產生重大影響。因此，採取兼顧全球集中協調和本地執行能力的區域性策略，將有助於最大限度地擴大患者覆蓋率並實現商業性的永續性。

透過將科學差異化與生產規模和以支付方為中心的證據產生相結合，使公司的策略行動和競爭策略保持一致。

急性髓系白血病（AML）治療生態系統中的主要企業正在尋求將深厚的科學差異化與切實可行的商業計劃相結合的策略。大型製藥企業正利用其成熟的商業基礎設施和全球開發經驗，加速後期專案的推進，並儘早與支付方展開對話。中型生物技術公司和細胞療法專家則專注於敏捷創新，瞄準分子定義的亞群，並尋求策略聯盟以彌補生產和全球市場准入方面的能力缺口。越來越多的公司正在進行合作，將專有平台與互補資產結合，以降低臨床試驗風險並擴大複雜生產流程的規模。

為了加快患者用藥速度，生產合作夥伴和委外研發機構正在投資一次性技術、封閉式細胞處理系統以及分散式填充和包裝解決方案，從而拓展先進療法的研發能力。同時，市場參與企業正著重採用差異化的臨床試驗設計，結合生物標記主導的入組和自適應終點，為監管機構和支付方提供強力的證據。商業性策略也反映出向價值定價、結果追蹤和綜合服務（包括診斷和患者支持）的轉變。那些能夠將臨床創新與穩健的供應鏈和符合支付方需求的證據產生相結合的公司，將在將科學成果轉化為永續的患者用藥方面保持競爭優勢。

為協調臨床開發、生產韌性和支付方參與，以加速藥物可及性和商業性成功，提出切實可行的策略建議。

產業領導者應採取一系列實際有效、影響深遠的行動，使研發重點與商業化實際情況相符，同時保障供應的連續性和與支付方的關係。首先，優先考慮以生物標記主導的臨床路徑和適應性試驗設計，以降低後期研發風險，並提高核准和報銷的可能性。其次，加速供應商網路多元化，考慮區域性生產投資以減少貿易中斷的影響，並加速產品惠及病患的速度。第三，在研發規劃早期階段就納入健康經濟學和結果研究，以產生基於價值的合約和差異化定價所需的真實世界證據。

此外，我們將促進跨領域夥伴關係，將研發平台與生產和分銷專長結合，以加速複雜療法的規模化生產。我們將投資於遠端患者監護和依從性支持的數位化工具，特別是針對口服和皮下注射療法，以展示其在真實世界中的療效，並支持基於結果的合約。最後，我們將積極與政策制定者和相關人員溝通，明確一次性治療和高成本治療的報銷途徑，並倡導監管協調，以減少及時獲得治療的行政障礙。這些措施將共同增強韌性，加速治療普及，並使商業性預期與臨床實際情況相符。

採用透明嚴謹的混合方法研究途徑，結合專家訪談、文獻回顧和證據三角驗證，確保獲得可靠的研究結果。

調查方法採用多層次、可重複的方法，結合定性和定量技術，以確保研究結果的穩健性和三角驗證。主要研究包括對臨床醫生、臨床實驗、支付方和行業高管進行結構化訪談，以了解臨床實踐、報銷動態和營運限制等方面的基層觀點。專家諮詢有助於對供應鏈中斷和監管變化進行情境分析，而臨床實驗的研究綜述則提供了有關真實世界治療模式和仿單標示外用藥的背景資訊。

二次研究包括對同行評審文獻、臨床試驗註冊庫、監管指南和公司披露資訊進行全面審查，以建立機制特異性療效和安全性特徵的依證。商業性資訊來自產品附加檔、會議論文集和公開競標，並評估了不同醫療機構的可近性。資料綜合採用定性編碼、比較框架分析以及與多個獨立資訊來源的交叉檢驗，以減少偏差並提高可靠性。透過記錄資料來源並對關鍵假設進行敏感度檢驗和專家檢驗，確保了調查方法的透明度。

這是一份簡明扼要、綜合全面的總結，重點闡述了為實現對患者的持續影響，臨床、生產和商業策略之間需要如何協調一致。

總之，急性髓系白血病（AML）治療領域呈現出以下特點：科學創新加速、監管環境和支付方預期不斷變化，以及日益複雜的運作模式重塑了患者獲得治療的途徑。成功的研發需要整合策略，將分子標靶的臨床開發與穩健的生產製造、符合支付方需求的證據生成以及本地化的商業化計劃相結合。積極應對供應鏈脆弱性、採用適應性臨床設計並儘早與支付方接洽的利益相關人員，將更有能力將治療方法進展轉化為永續的臨床和商業性成果。

精準診斷、先進生技藥品和細胞療法的未來融合，若能促使產業相關人員在科學、監管和商業領域通力合作，將顯著改善病患的治療效果。透過將能力建構投資與策略夥伴關係結合，並在整個研發過程中融入衛生經濟學理念，企業可以克服複雜性，為病患和醫療保健系統創造實際價值。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

• FLT3抑制劑在急性髓性白血病（AML）一線治療和復發/難治性患者治療中的出現，以及生存率的提高，都促進了AML患者的康復。
• 擴大MLL基因重排和NPM1基因突變的menin抑制劑治療急性骨髓性白血病的臨床試驗
• 針對 CD33 和 CD123 抗原的雙特異性 T 細胞銜接器的開發推動了急性髓性白血病 (AML) 免疫療法的創新。
• 利用次世代定序，結合微小殘留病灶（MRD）所指導的治療調整，實現急性髓性白血病（AML）治療策略的個人化。
• 一種口服BCL-2抑制劑療法核准並上市，為老年急性髓系白血病（AML）患者提供了一種無需化療的選擇。
• 研究針對急性髓性白血病特異性抗原的CAR-T細胞療法，以克服復發病例的治療抗藥性
• 採用標靶表觀遺傳調變器（例如 IDH1/2 抑制劑）將重塑急性髓系白血病 (AML) 的治療模式。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章急性骨髓性白血病藥物市場（依治療類型分類）

• 生物製藥
  • 抗體藥物複合體
  • 融合蛋白
  • 單株抗體
• 細胞療法
  • CAR-T細胞療法
  • 幹細胞移植
• 基因治療
• 小分子
  • BCL-2抑制劑
  • DNA甲基轉移酵素酶抑制劑
  • 蛋白酪氨酸激酶抑制劑
    • FLT3抑制劑
    • KIT抑制劑

第9章急性骨髓性白血病藥物市場依作用機轉分類

• BCL-2抑制劑
• DNA甲基轉移酵素酶抑制劑
• HDAC抑制劑
• 免疫調節藥物
• 蛋白酪氨酸激酶抑制劑

第10章急性骨髓性白血病藥物市場治療方案

• 第一排
• 第二行
• 三線及以後

第11章急性骨髓性白血病藥物市場（按最終用戶分類）

• 醫院藥房
• 零售藥房
• 專科診所

第12章急性骨髓性白血病藥物市場依給藥途徑分類

• 靜脈
• 口服
• 皮下

第13章 依患者年齡分類的急性骨髓性白血病藥物市場

• 成人版
• 老年人
• 孩子們

第14章急性骨髓性白血病藥物市場（按地區分類）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第15章急性骨髓性白血病藥物市場（依組別分類）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第16章 各國急性骨髓性白血病藥物市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第17章 競爭格局

• 2024年市佔率分析
• FPNV定位矩陣，2024
• 競爭分析
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Jazz Pharmaceuticals plc
  • Novartis AG
  • Bristol Myers Squibb Company
  • Astellas Pharma Inc.
  • Agios Pharmaceuticals, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Company, Limited

The Acute Myeloid Leukemia Therapeutics Market is projected to grow by USD 2.61 billion at a CAGR of 12.46% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 1.02 billion
Estimated Year [2025]	USD 1.14 billion
Forecast Year [2032]	USD 2.61 billion
CAGR (%)	12.46%

A concise foundational overview of acute myeloid leukemia therapeutic evolution highlighting clinical complexity, precision approaches, and commercial imperatives

Acute myeloid leukemia (AML) remains one of the most clinically complex hematologic malignancies, characterized by heterogeneous genetic drivers, variable patient demographics, and evolving therapeutic paradigms. Over the past decade, the therapeutic landscape has shifted from broadly cytotoxic regimens toward precision-targeted approaches and immuno-oncology modalities. This transition has been driven by deeper molecular understanding, improved diagnostic stratification, and maturation of advanced biologics and cellular therapies. Consequently, stakeholders across research, clinical practice, and commercial functions face a rapidly changing environment that demands adaptive strategies.

Clinicians now balance established induction-maintenance frameworks with an expanding armamentarium of targeted inhibitors, epigenetic modulators, and cell-based interventions. At the same time, payers and provider systems are adapting reimbursement approaches to account for high-cost one-time therapies and long-term outcomes. These dynamics create both opportunities and operational complexities for manufacturers, contract development and manufacturing organizations, and supply-chain partners. Therefore, a clear, actionable synthesis of clinical trends, regulatory shifts, and commercial imperatives is essential for leaders making investment, alliance, and launch decisions in the AML therapeutics arena.

An authoritative examination of the converging scientific, regulatory, and commercial forces reshaping acute myeloid leukemia therapy development and access

The AML therapeutic landscape is experiencing transformative shifts driven by converging scientific advances, regulatory evolution, and commercial innovation. Precision medicine has moved from concept to clinical routine as genomic profiling and minimal residual disease assays enable more refined patient selection and adaptive treatment strategies. This shift is complemented by the maturation of biologic platforms, including antibody drug conjugates and fusion proteins, that extend the therapeutic index and permit targeted cytotoxic delivery. Simultaneously, the development and scaling of cell therapies have introduced durable response potential while imposing unique manufacturing and logistics requirements.

Concurrently, regulatory pathways are evolving to accommodate novel modalities and surrogate endpoints, which accelerates time-to-access but also raises evidentiary demands for long-term safety and real-world effectiveness. Payers are responding with value-based contracting pilots and outcomes-based reimbursement models that link upfront cost to durability of response. Industry partnerships are proliferating to pool expertise across discovery, translational science, and commercial access, altering traditional competitive dynamics. As a result, success increasingly depends on integrated strategies that align clinical development with supply-chain readiness and payer engagement, rather than isolated product-centered plans.

A clear analysis of cumulative trade policy impacts on AML therapeutic supply chains, manufacturing investment choices, and access considerations in 2025

The introduction of elevated tariff regimes and trade policy shifts in 2025 created tangible ripple effects across the AML therapeutics value chain, with cumulative impacts centering on supply-chain resilience, manufacturing strategy, and cost-to-patient dynamics. Import-dependent components used in biologics and cell therapy manufacturing, including specialized reagents, single-use systems, and critical equipment, saw altered procurement profiles that prompted manufacturers and contract partners to reassess sourcing geographies and inventory buffers. In response, several stakeholders accelerated nearshoring initiatives and diversified supplier networks to mitigate exposure to tariff-related disruptions.

Beyond procurement, tariffs influenced capital expenditure decisions for new manufacturing capacity, particularly for complex modalities that require specialized clean-room facilities and cold-chain infrastructure. Firms contemplating new plants weighed increased import duties on equipment and spare parts against long-term strategic imperatives for regional supply security. Moreover, higher landed costs for imported materials exerted pressure on pricing negotiations and distributor agreements, which in turn affected hospital and specialty clinic budgets for oncology therapeutics. These pressures reinforced the need for transparent cost-of-goods analyses and collaborative contracting mechanisms between manufacturers and payers.

Finally, tariffs intensified the focus on regulatory and customs harmonization to reduce administrative delays that compound the financial impact of trade measures. Stakeholders increasingly sought engagement with policymakers and industry associations to clarify tariff classifications for biologic and advanced therapy components, and to advocate for exemptions where national health priorities justified rapid access. As a consequence, companies that proactively adapted procurement strategies, reinforced regional manufacturing footprints, and engaged constructively with policymakers were better positioned to preserve supply continuity and protect patient access amid the changing trade environment.

Comprehensive segmentation analysis revealing how therapy modality, mechanism, care setting, administration route, and patient demographics define clinical and commercial strategies

Segmentation insights reveal differentiated opportunities and operational demands across therapy types, mechanisms, lines of therapy, end users, routes of administration, and patient age cohorts. Therapeutic modality choices span biologic options such as antibody drug conjugates, fusion proteins, and monoclonal antibodies; cell therapies including CAR T approaches and stem cell transplantation; gene therapies; and a range of small molecules where BCL-2 inhibitors, DNA methyltransferase inhibitors, and tyrosine kinase inhibitors, with further subdivision into FLT3 and KIT targeted agents, play a central role. These modality distinctions carry distinct implications for clinical trial design, manufacturing complexity, and post-approval evidence generation.

Mechanism-focused segmentation underscores how BCL-2 inhibition, epigenetic modulation via DNA methyltransferase inhibitors, histone deacetylase modulation, immunomodulatory agents, and tyrosine kinase inhibition differentially influence combination strategies and resistance management. In terms of line of therapy, first-line paradigms prioritize durability and tolerability in newly diagnosed populations, second-line treatments emphasize salvage efficacy and safety, and third-line and beyond options concentrate on overcoming acquired resistance and managing cumulative toxicity. End-user segmentation highlights that hospital pharmacies must coordinate inpatient administration and cold-chain storage for complex biologics, retail pharmacies navigate outpatient dispensing of oral regimens, and specialty clinics deliver advanced cellular therapies under highly controlled conditions.

Route-of-administration segmentation differentiates intravenous therapies that demand infusion infrastructure and monitoring from oral agents that enable at-home dosing but require adherence support, while subcutaneous options can reduce infusion burdens yet require patient education and administration training. Patient age segmentation shows that adult cohorts constitute the bulk of treatment decisions with geriatric populations often necessitating adapted dosing and comorbidity management, whereas pediatric cases require bespoke safety and developmental considerations. Integrating these segmentation lenses enables stakeholders to prioritize clinical development pathways, align manufacturing and distribution investments, and design differentiated market access approaches tailored to modality, mechanism, care setting, and patient demographics.

An in-depth regional perspective highlighting differentiated adoption drivers, regulatory expectations, and operational priorities across major global markets

Regional insights underscore divergent drivers of adoption, regulatory expectations, and operational priorities across the Americas, Europe Middle East and Africa, and Asia-Pacific regions, each presenting unique implications for clinical development and commercialization. In the Americas, fragmented payer landscapes and advanced reimbursement mechanisms coexist with robust clinical trial networks and established oncology centers, creating an environment where evidence generation and value demonstration are critical to premium access and uptake. Conversely, Europe Middle East and Africa encompasses a mix of centralized regulatory frameworks and variable reimbursement thresholds, which heightens the importance of health technology assessment alignment and regional pricing strategies.

Asia-Pacific presents accelerated adoption potential driven by large patient populations, growing diagnostic capabilities, and expanding manufacturing capacity, yet it also features diverse regulatory regimes and cost-sensitivity that necessitate regionalized clinical development plans and flexible commercial models. Across all regions, logistical considerations such as cold-chain robustness, local manufacturing partnerships, and expedited regulatory engagement materially affect launch sequencing and access timelines. Therefore, a regionally nuanced approach that balances centralized global coordination with local execution capacity will optimize patient reach and commercial sustainability.

Strategic company behaviors and competitive alignments that combine scientific differentiation with manufacturing scale and payer-focused evidence generation

Leading companies in the AML therapeutics ecosystem are pursuing strategies that blend deep scientific differentiation with pragmatic commercial planning. Large pharmaceutical organizations are leveraging established commercial infrastructure and global development expertise to accelerate late-stage programs and to secure payer conversations early. Mid-sized biotechs and specialized cell therapy firms focus on nimble innovation, targeting molecularly defined subpopulations and pursuing strategic collaborations to fill capability gaps in manufacturing and global access. Across the board, companies are increasingly forming alliances that combine proprietary platforms with complementary assets to de-risk clinical pathways and to scale complex manufacturing processes.

Manufacturing partners and contract development organizations are scaling capabilities for advanced modalities, investing in single-use technologies, closed-system cell processing, and decentralized fill-finish solutions to support faster patient access. At the same time, market entrants emphasize differentiated clinical trial designs that incorporate biomarker-driven enrollment and adaptive endpoints to generate compelling evidence for regulators and payers. Commercial playbooks reflect a shift toward value-based pricing discussions, outcomes tracking, and integrated service offerings that include diagnostics and patient support. Firms that integrate clinical innovation with supply-chain robustness and payer-aligned evidence generation maintain a competitive advantage in translating scientific promise into sustainable patient access.

Actionable strategic recommendations that align clinical development, manufacturing resilience, and payer engagement to accelerate access and commercial success

Industry leaders should pursue a set of pragmatic, high-impact actions that align R&D priorities with commercialization realities while safeguarding supply continuity and payer relationships. First, prioritize biomarker-driven clinical pathways and adaptive trial designs that de-risk late-stage development and enhance the probability of regulatory approval and reimbursement. Second, accelerate diversification of supplier networks and consider regional manufacturing investments to reduce exposure to trade-related disruptions and to shorten time-to-patient. Third, embed health economics and outcomes research early in development plans to generate the real-world evidence required for value-based contracting and to support differentiated pricing conversations.

Moreover, cultivate cross-sector partnerships that combine discovery platforms with manufacturing and distribution expertise to accelerate scale-up of complex modalities. Invest in digital tools for remote patient monitoring and adherence support, particularly for oral and subcutaneous therapies, to demonstrate real-world effectiveness and to support outcomes-based agreements. Finally, engage proactively with policymakers and payer stakeholders to clarify reimbursement pathways for one-time and high-cost therapies, and to advocate for regulatory harmonization that reduces administrative barriers to timely access. Collectively, these actions will strengthen resilience, expedite access, and align commercial expectations with clinical realities.

A transparent and rigorous mixed-methods research approach combining primary expert interviews, secondary literature review, and evidence triangulation to ensure dependable insights

The research methodology employed a layered and reproducible approach combining both qualitative and quantitative techniques to ensure robustness and triangulation of findings. Primary research included structured interviews with clinicians, clinical trial investigators, payers, and industry executives to capture frontline perspectives on clinical practice, reimbursement dynamics, and operational constraints. Expert consultations informed scenario analyses around supply-chain disruptions and regulatory shifts, while investigator-initiated study reviews provided context for real-world treatment patterns and off-label usage.

Secondary research encompassed a comprehensive review of peer-reviewed literature, clinical trial registries, regulatory guidances, and company disclosures to construct an evidence base for mechanism-specific efficacy and safety profiles. Commercial intelligence was derived from product labeling, conference proceedings, and public tenders to assess accessibility considerations across care settings. Data synthesis applied qualitative coding, comparative framework analysis, and cross-validation against multiple independent sources to reduce bias and to enhance credibility. Throughout, methodological transparency was maintained by documenting data provenance and by subjecting key assumptions to sensitivity checks and expert validation.

A concise integrative synthesis emphasizing coordinated clinical, manufacturing, and commercial strategies required to realize durable patient impact

In conclusion, the AML therapeutics landscape is characterized by accelerated scientific innovation, shifting regulatory and payer expectations, and evolving operational complexities that together redefine pathways to patient access. Success requires integrated strategies that pair molecularly targeted clinical development with resilient manufacturing, payer-aligned evidence generation, and regionally tailored commercialization plans. Stakeholders that proactively address supply-chain vulnerabilities, adopt adaptive clinical designs, and engage payers early will be better equipped to translate therapeutic advances into sustainable clinical and commercial outcomes.

Looking ahead, the intersection of precision diagnostics, advanced biologics, and cell therapies presents substantial promise for improving patient outcomes, provided that industry actors coordinate across scientific, regulatory, and commercial domains. By aligning investments in capability building with strategic partnerships and by embedding health-economic thinking throughout development programs, organizations can navigate complexity and deliver meaningful value to patients and healthcare systems alike.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Emergence of FLT3 inhibitors in frontline and relapsed/refractory AML treatment landscape with improved survival outcomes
• 5.2. Expansion of menin inhibitors targeting MLL-rearranged and NPM1-mutant acute myeloid leukemia in clinical trials
• 5.3. Development of bispecific T-cell engagers against CD33 and CD123 antigens driving immunotherapy innovation in AML
• 5.4. Integration of MRD-guided therapy adjustments using next-generation sequencing to personalize AML treatment strategies
• 5.5. Approval and commercialization of oral BCL-2 inhibitor regimens offering chemo-free options for elderly AML patients
• 5.6. Investigation of CAR-T cell therapies targeting AML-specific antigens to overcome treatment resistance in relapsed cases
• 5.7. Adoption of targeted epigenetic modulators like IDH1/2 inhibitors shaping the therapeutic paradigm in AML management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Myeloid Leukemia Therapeutics Market, by Therapy Type

• 8.1. Biologic
  • 8.1.1. Antibody Drug Conjugates
  • 8.1.2. Fusion Proteins
  • 8.1.3. Monoclonal Antibodies
• 8.2. Cell Therapy
  • 8.2.1. CAR T Cell Therapy
  • 8.2.2. Stem Cell Transplantation
• 8.3. Gene Therapy
• 8.4. Small Molecule
  • 8.4.1. BCL-2 Inhibitors
  • 8.4.2. DNA Methyltransferase Inhibitors
  • 8.4.3. Tyrosine Kinase Inhibitors
    • 8.4.3.1. FLT3 Inhibitors
    • 8.4.3.2. KIT Inhibitors

9. Acute Myeloid Leukemia Therapeutics Market, by Mechanism Of Action

• 9.1. BCL-2 Inhibitors
• 9.2. DNA Methyltransferase Inhibitors
• 9.3. HDAC Inhibitors
• 9.4. Immunomodulatory Agents
• 9.5. Tyrosine Kinase Inhibitors

10. Acute Myeloid Leukemia Therapeutics Market, by Line Of Therapy

• 10.1. First Line
• 10.2. Second Line
• 10.3. Third Line And Beyond

11. Acute Myeloid Leukemia Therapeutics Market, by End User

• 11.1. Hospital Pharmacy
• 11.2. Retail Pharmacy
• 11.3. Specialty Clinic

12. Acute Myeloid Leukemia Therapeutics Market, by Route Of Administration

• 12.1. Intravenous
• 12.2. Oral
• 12.3. Subcutaneous

13. Acute Myeloid Leukemia Therapeutics Market, by Patient Age

• 13.1. Adult
• 13.2. Geriatric
• 13.3. Pediatric

14. Acute Myeloid Leukemia Therapeutics Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Acute Myeloid Leukemia Therapeutics Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Acute Myeloid Leukemia Therapeutics Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. AbbVie Inc.
  • 17.3.2. F. Hoffmann-La Roche Ltd
  • 17.3.3. Pfizer Inc.
  • 17.3.4. Jazz Pharmaceuticals plc
  • 17.3.5. Novartis AG
  • 17.3.6. Bristol Myers Squibb Company
  • 17.3.7. Astellas Pharma Inc.
  • 17.3.8. Agios Pharmaceuticals, Inc.
  • 17.3.9. Otsuka Pharmaceutical Co., Ltd.
  • 17.3.10. Daiichi Sankyo Company, Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FLT3 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY KIT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 221. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
• TABLE 222. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2032 (USD MILLION)
• TABLE 223. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 224. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 225. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 226. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 227. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 228. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 229. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 230. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 231. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 232. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 233. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 234. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 239. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
• TABLE 240. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
• TABLE 241. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 242. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 243. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
• TABLE 244. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2032 (USD MILLION)
• TABLE 245. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 246. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 247. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 248. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 249. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 250. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 251. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 252. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 253. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 254. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 255. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 256. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
• TABLE 257. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 260. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 261. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
• TABLE 262. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
• TABLE 263. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 264. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 265. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
• TABLE 266. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, 2025-2032 (USD MILLION)
• TABLE 267. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 268. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 269. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 270. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 271. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 272. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 273. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 274. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 275. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET